Efficacy of CoQ10 as supplementation for migraine: A meta-analysis

Acta Neurol Scand. 2019 Mar;139(3):284-293. doi: 10.1111/ane.13051. Epub 2018 Dec 3.


Objectives: Migraine ranks among the most frequent neurological disorders globally. Co-enzyme Q10 (CoQ10) is a nutritional agent that might play a preventative role in migraine. This meta-analysis aimed to investigate the effects of CoQ10 as a supplemental agent in migraine.

Subjects and methods: Web of Science, PubMed, and Cochrane Library were searched for potential articles that assessed the effects of CoQ10 on migraine. Data were extracted by two independent reviewers and analyzed with Revman 5.2 software (The Nordic Cochrane Centre, Copenhagen, Denmark).

Results: We included five studies with 346 patients (120 pediatric and 226 adult subjects) in the meta-analysis. CoQ10 was comparable with placebo with respect to migraine attacks/month (P = 0.08) and migraine severity/day (P = 0.08). However, CoQ10 was more effective than placebo in reducing migraine days/month (P < 0.00001) and migraine duration (P = 0.009).

Conclusion: This is the first study to demonstrate the effects of CoQ10 supplementation on migraine. The results support the use of CoQ10 as a potent therapeutic agent with respect to migraine duration and migraine days/month. Nonetheless, more studies are needed to support the conclusions.

Keywords: CoQ10; headache; meta-analysis; migraine; supplementation.

Publication types

  • Meta-Analysis

MeSH terms

  • Adult
  • Denmark
  • Humans
  • Migraine Disorders / drug therapy*
  • Ubiquinone / analogs & derivatives*
  • Ubiquinone / therapeutic use


  • Ubiquinone
  • coenzyme Q10